Reunion Neuroscience

Reunion Neuroscience is a Montreal-based neurotechnology company focused on developing next-generation psychedelic compounds for the treatment of mental health disorders. The company's lead asset, RE104, is a novel 4-phosphoryloxy-N,N-diethyltryptamine compound designed to produce psychedelic effects with a significantly shorter duration of action compared to traditional psilocybin therapy. This shorter duration aims to reduce the clinical burden associated with current psychedelic-assisted therapy models, which often require extended supervised sessions lasting six to eight hours. Reunion is advancing RE104 with a primary focus on postpartum depression and major depressive disorder, two conditions with substantial unmet therapeutic need. The company trades publicly on the NASDAQ under the ticker symbol REUN, providing it with capital market access to fund its clinical development programs.

Reunion Neuroscience has positioned itself within the emerging psychedelic medicine sector at a time of growing regulatory and investor interest in alternative mental health treatments. The company has advanced RE104 into clinical trials, targeting postpartum depression as an initial indication given the urgency of the condition and the limited treatment options currently available to affected patients. Their clinical strategy reflects a broader effort to generate rigorous safety and efficacy data that could support regulatory approval and eventual commercial adoption. By focusing on a differentiated compound rather than repurposing existing psychedelics, Reunion is building a proprietary platform with potential intellectual property advantages in a competitive landscape. Their public listing has enabled the company to raise capital and increase visibility among institutional investors tracking the psychedelic medicine space.

Reunion Neuroscience represents an important example of how the neurotech and psychedelic medicine industries are converging around the need for more practical, scalable treatment modalities. The limitations of long-duration psychedelic therapies have been a significant barrier to clinical adoption and health system integration, and RE104 directly addresses this gap by engineering a compound optimized for real-world therapeutic settings. If successful, their approach could help normalize psychedelic-assisted therapy within mainstream psychiatric care and set a precedent for how novel compounds can be developed to improve upon the practicality of first-generation psychedelics. Reunion's work also underscores the broader shift in mental health treatment toward neurobiologically targeted interventions that go beyond conventional pharmacology. As the regulatory environment for psychedelic medicine continues to evolve, companies like Reunion are helping to define the standards and infrastructure for this emerging category of neurotherapeutics.